FARON PHARMACEUTICALS OY

AGM Information • May 26, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4092Z

Faron Pharmaceuticals Oy

26 May 2016

Faron Pharmaceuticals Ltd

("Faron" or the "Company")

Result of Annual General Meeting

TURKU - FINLAND 26 May 2016 - Faron Pharmaceuticals Ltd (LON: FARN) is pleased to announce that all resolutions proposed at its Annual General Meeting held today and as set out in the Company's announcement dated 4 May 2016, were duly passed by shareholders.

Commenting on the meeting, Frank Armstrong, Chairman of Faron, said: "We are delighted to have such support from our shareholders at the very first Annual General Meeting as a listed company. We thank our shareholders for sharing Faron´s mission of life-saving drug development. We are looking forward to making further significant progress with our innovations to develop new treatments for true unmet medical needs."

For more information, please contact:

Faron Pharmaceuticals Oy

Katja Wallenlind

Phone +358 (50) 577 4807

E-mail: katja.wallenlind@faronpharmaceuticals.com

Cairn Financial Advisers LLP, Nominated Adviser

Emma Earl, Tony Rawlinson and Rebecca Anderson

Phone: +44 207 148 7900

Panmure Gordon (UK) Limited, Joint Broker

Freddy Crossley, Duncan Monteith (Corporate Finance)

Tom Salvesen (Corporate Broking)

Phone: +44 207 886 2500

Whitman Howard Limited, Nominated Broker

Ranald McGregor-Smith, Francis North

Phone: +44 207 659 1234

Hume Brophy, PR

Mary Clark, Eva Haas, Hollie Vile

Phone: +44 207 862 6390

E-mail: faron@humebrophy.com

About Faron Pharmaceuticals Ltd.

Faron is a drug discovery and development company focused on creating novel treatments for medical conditions with significant unmet needs. The Company is based in Turku, Finland. The Company currently has a pipeline of clinical stage products focusing on acute organ traumas, cancer immunotherapy and vascular damage. The Company's lead candidate Traumakine®, has been developed to treat acute respiratory distress syndrome ("ARDS"), a rare, severe, life threatening medical condition characterised by widespread inflammation in the lungs. Traumakine® is now in a pan-European pivotal Phase III study (INTEREST). Besides Traumakine®, Faron's pipeline consists of early stage assets including a pre-clinical anti-Clever-1 antibody named Clevegen. Clevegen is focused on converting the immune environment around a tumour from being immune suppressive to immune stimulating and represents a novel immuno-oncology approach called TIET (Tumour Immunity Enabling Technology). Faron Pharmaceuticals Ltd. is listed on AIM under the ticker 'FARN'. Further information is available at www.faronpharmaceuticals.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGLIFEAELIRFIR